(AMEX: CTU);(NASDAQ: ARIA); (NYSE: MWV); (NASDAQ: AVCT); (NASDAQ: HSIC).

RealPennies.com: Turning Pennies into dollars: (AMEX: CTU);(NASDAQ: ARIA); (NYSE: MWV); (NASDAQ: AVCT); (NASDAQ: HSIC).

Are you a public company looking for exposure?
Contact RealPennies.com - 1.800.940.6559

For more info: http://ctu.realpennies.com

CHAD Therapeutics, Inc. (AMEX: CTU) (Wed. January 2, 2008) announced earlier today that it has commenced mailing its definitive proxy statement to shareholders for approval of its proposed sale of assets related to its oxygen conserving business to Inovo, Inc., a privately held manufacturer of oxygen regulators and conservers based in Naples, Florida, pursuant to an asset purchase agreement dated November 16, 2007. The Company has scheduled a special meeting of shareholders for Thursday, January 31, 2008, at 10:00 a.m. PST at CHAD Therapeutics, Inc, 21622 Plummer Street, Chatsworth, CA, 91311. Shareholders of record as of the close of business on December 24, 2007, will be entitled to vote at the meeting.

The Company's Board of Directors has unanimously determined that the proposed asset sale is in the best interests of the Company and its shareholders and recommends that shareholders vote "FOR" the proposed sale.

Shareholders are encouraged to read the Company's definitive proxy materials in their entirety. The proxy materials, which were mailed on or about December 28, 2007, provide, among other things, a detailed discussion of the process that led to the proposed asset sale, the reasons behind the Board of Directors' unanimous recommendation and the risks involved with the sale. Additional copies of the proxy statement are available without charge from CHAD and also may be obtained for free from the SEC's website at www.sec.gov. Stockholders who have questions about the asset sale or need assistance in submitting their proxy or voting their shares should contact the Company's proxy solicitor, Morrow & Co., LLC, toll free at 1-800-662-5200.

Earl Yager, CHAD's President and CEO said, "Approval of the asset sale is critical to CHAD's future. Because failure to vote will have the same effect as a vote against approving the transaction, we urge shareholders to exercise their rights by voting their shares as soon as possible after they receive and review the proxy statement."

CHAD Therapeutics, Inc. develops, manufactures and markets respiratory care devices designed to improve the efficiency of oxygen delivery systems for home health care and hospital treatment of patients suffering from pulmonary diseases.

For more info: http://aria.realpennies.com

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) earlier today announced that it will present at the 26th Annual JPMorgan Healthcare Conference, being held January 7-10, 2008 at the Westin St. Francis Hotel in San Francisco, California. Harvey J. Berger, M.D., chairman and chief executive officer at ARIAD, will provide a company overview on Wednesday, January 9 at 11:30 a.m. (PT), highlighting the global clinical development plan for ARIAD's lead product deforolimus, as well as top-line financial guidance for the Company's fiscal year 2008.

ARIAD is engaged in the discovery and development of breakthrough medicines to treat cancer by regulating cell signaling with small molecules. ARIAD is developing a comprehensive approach to patients with cancer that addresses the greatest medical need - aggressive and advanced-stage cancers for which current treatments are inadequate. ARIAD has a global partnership with Merck & Co., Inc. to develop and commercialize deforolimus, ARIAD's lead cancer product candidate. Medinol Ltd. and ICON Medical Corp. are also developing deforolimus-eluting stents to prevent restenosis of injured vessels following interventions in which stents are used in conjunction with balloon angioplasty.

For more info: http://mwv.realpennies.com

MeadWestvaco Corporation (NYSE: MWV) announced earlier today they will release its results for the fourth quarter 2007 on Friday, February 1, 2008, before the market opens. The news release for fourth quarter results will be available on MeadWestvaco's website at www.meadwestvaco.com.

The company will broadcast its fourth quarter analyst conference call on Friday, February 1, 2008, at 10:00 a.m. (EST) with access available via Internet and telephone. The teleconference is expected to last about one hour. John A. Luke, Jr., chairman and chief executive officer; James A. Buzzard, president; E. Mark Rajkowski, chief financial officer; and Jason Thompson, director, investor relations, will review the fourth quarter results. Following the review, questions will be taken from registered analysts and investors.

Investors may participate in the live conference call by dialing 1 (888) 423-3271 (toll-free domestic) or 1 (612) 332-0923 (international); passcode: MeadWestvaco. Please call to register at least 10 minutes before the conference call begins. A replay of the call will be available for one month via the telephone starting at 1:30 p.m. (EST) on February 1, and can be accessed at 1 (800) 475-6701 (toll-free domestic) or 1 (320) 365-3844 (international); access code: 891607.

The live conference call and presentation slides may be accessed on MeadWestvaco's website at www.meadwestvaco.com. After connecting to the home page, look for the link to Investor Information, then Financial Calendar, to access the webcast. Please go to the website at least one hour prior to the call to register, download and install any necessary audio software.

MeadWestvaco Corporation (NYSE: MWV) provides packaging solutions to many of the world's most-admired brands in the food and beverage, media and entertainment, personal care, home and garden, cosmetics, and healthcare industries. The company has market-leading positions in its Consumer & Office Products and Specialty Chemicals businesses, and operates in more than 30 countries. MeadWestvaco manages all of its forestlands in accordance with internationally recognized forest certification standards, and has been named to the Dow Jones Sustainability World Index for the fourth consecutive year.

For more info: http://avct.realpennies.com

Avocent Corporation (NASDAQ: AVCT) earlier today announced that Edward H. Blankenship, Senior Vice President of Finance and Chief Financial Officer, and Everett Brooks, Vice President of Investor Relations, will present at the Needham & Company, LLC 10th Annual Growth Conference on Wednesday, January 9, 2008, at 2:30 p.m. Central Time. The event is being held at The New York Palace Hotel in New York.

The live webcast of Avocent's presentation will be available on the Company's website, www.avocent.com, by clicking on the "Investor Relations" link or at: http://www.wsw.com/webcast/needham21/avct/. A replay of the presentation will be available shortly after its conclusion at the Company's website for 30 days.

About Avocent Corporation

Avocent delivers IT operations and infrastructure management solutions for enterprises worldwide, helping customers to reduce costs and simplify complex IT environments via integrated, centralized in-band and out-of-band hardware and software. Through LANDesk, Avocent also is a leading provider of systems, security, and process management solutions. Additional information is available at: www.avocent.com.

For more info: http://hsic.realpennies.com

Henry Schein, Inc., (NASDAQ: HSIC), the largest provider of healthcare products and services to office-based practitioners in the combined North American and European markets, announced earlier today that Stanley M. Bergman, Henry Schein's Chairman and Chief Executive Officer, and Steven Paladino, Henry Schein's Executive Vice President and Chief Financial Officer, will present at the 26th Annual JPMorgan Healthcare Conference on Monday, January 7, 2008. The Conference is being held at The Westin St. Francis Hotel in San Francisco, CA.

Henry Schein's presentation is scheduled to begin at 11:30 a.m. EST and can be heard via live webcast by visiting www.henryschein.com, clicking on "Investor Relations" and following the link for "Webcasts." A replay will be available on the web site following the presentation.

Henry Schein, a Fortune 500 company and a member of the NASDAQ 100 Index, is recognized for its excellent customer service and highly competitive prices. The Company's four business groups - Dental, Medical, International and Technology - serve more than 500,000 customers worldwide, including dental practitioners and laboratories, physician practices and animal health clinics, as well as government and other institutions. The Company operates through a centralized and automated distribution network, which provides customers in more than 200 countries with a comprehensive selection of more than 85,000 national and Henry Schein private-brand products in stock, as well as more than 100,000 additional products available as special-order items.

Henry Schein also offers a wide range of innovative value-added practice solutions for healthcare professionals, such as ArubA , the Company's electronic catalog and ordering system. Its leading practice-management software solutions have been installed in more than 50,000 practices, including DENTRIX and Easy Dental for dental practices, MicroMD for physician practices, and AVImark for animal health clinics.

Headquartered in Melville, N.Y., Henry Schein employs over 12,000 people and has operations or affiliates in 22 countries. The Company's net sales reached a record $5.05 billion in 2006.

Read our full disclaimer at: http://www.realpennies.com/start.html

Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned on RealPennies. For more movers: http://www.realpennies.com/wrapup.html

Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice.
Sitemap: http://www.realpennies.com/sitemap.html

RealPennies .

Telephone: 1-800-940-6559

Matt /at/ realpennies.com